John G. Watson Foundation Board Members
The John G. Watson Foundation is led by a Board of Directors comprised of experienced representatives from leading local businesses with diverse professional backgrounds.
Dean is Chairman of the San Diego Chapter of Tech Coast Angels (TCA), one of the largest early stage investment groups in the US. He has been an active entrepreneur within the San Diego start-up ecosystem since 1989, raising over $30M in venture capital. His last software company, AIRSIS, Inc. was funded by TCA and acquired by a public company in 2014. Dean is now a “professional” angel investor and is active in over 25 companies.
Dr. Flaim holds a doctorate in Human Physiology and Pharmacology from the University of California at Davis. He held faculty positions in Medicine and Physiology at the Pennsylvania State University College of Medicine and senior management roles at the Johnson & Johnson Pharmaceutical Research Institute, the Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation, Trega Biosciences, Inc. and Galileo Pharmaceuticals, Inc. Dr. Flaim is Founder and President of Flaim Partners Consulting, a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a board member of Pivotal Biosciences, Inc., Chairman of the Board for Leading Biosciences, Inc. and he is a member of the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics.
Dr. Flaim is Director of the Angel Capital Association, Past Chairman of the Board of Governors for the Tech Coast Angels, Past President and Chairman of the San Diego Network of Tech Coast Angels, an Entrepreneur-in-Residence with CONNECT, CEO of the John G. Watson Foundation and is active in numerous regional and national scientific organizations. He is a technology and business advisor to the William J. von Liebig Center for Entrepreneurism and Technology Advancement at the University of California, San Diego, Co-founder and CEO of CardioCreate, Inc., Chairman & CEO of OncoFluor, Inc. and Senior Special Advisor and Investor in Residence to the Office of Translational Alliances and Coordination in the Division of Extramural Research Activities of the National Heart, Lung and Blood Institutes of the National Institutes of Health.
Ned Israelsen is a co-founder and senior advisor to CardioCreate, Inc. He has been an active investor and participant in a number of life science startup companies. He is also the managing partner of the San Diego office of Knobbe Martens Olson & Bear LLP, managing 120 lawyers and staff. Ned received his Juris Doctorate from the George Washington University National Law Center with High Honors and Order of the Coif. He served for two years as a law clerk to the Court of Appeals for the Federal Circuit; taught law school at Loyola Marymount, Los Angeles and California Western School of Law; and has been a lecturer on law, entrepreneurship, and venture funding at University of San Diego Law School and the UC San Diego Rady School of Management. Ned is a Magna Cum Laude graduate of Utah State University.
He is currently treasurer and governing board member of the San Diego branch of Tech Coast Angels, the nation’s largest angel investing network. Ned has assisted dozens of innovative companies in the intellectual property aspects of private equity financing, initial public offerings, major licensing transactions, and corporate acquisitions, including InterMune, Inc., Somaxon Pharmaceuticals, Orexigen Pharmaceuticals, and NovaCardia, Inc. He has been honored as one of The Best Lawyers in America; Top Lawyers in San Diego; Worldwide Top IP Lawyers; and is also honored in both the Southern California Super Lawyers Edition and the Super Lawyers Corporate Counsel Edition. Ned was named one of San Diego’s 120 Most Influential Individuals, and was selected from the 217,000 members of the California State Bar as one of the Top 100 Lawyers in California.